{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:09:30Z","timestamp":1788851370430,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03757-3","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:45:04Z","timestamp":1788849904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-5142","authenticated-orcid":false,"given":"Kazumasa","family":"Kamei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Enami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"3757_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","volume":"28","author":"A Kaser","year":"2010","unstructured":"Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573\u2013621. https:\/\/doi.org\/10.1146\/annurev-immunol-030409-101225.","journal-title":"Annu Rev Immunol"},{"key":"3757_CR2","unstructured":"Ministry of Health, Labour and Welfare. Overview, diagnostic criteria, and clinical survey forms for designated intractable diseases (as of April 2026). https:\/\/translation.mhlw.go.jp\/LUCMHLW\/ns\/tl.cgi\/https:\/www.mhlw.go.jp\/stf\/newpage_53881.html?SLANG=ja&TLANG=en&XMODE=0&XCHARSET=utf-8&XJSID=0. Accessed 9 Apr 2026."},{"issue":"12","key":"3757_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00535-025-02295-z","volume":"60","author":"A Tsutsui","year":"2025","unstructured":"Tsutsui A, Murakami Y, Nishiwaki Y, et al. Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn\u2019s disease in Japan in 2023. J Gastroenterol. 2025;60(12):1513\u201322. https:\/\/doi.org\/10.1007\/s00535-025-02295-z.","journal-title":"J Gastroenterol"},{"key":"3757_CR4","unstructured":"Hisamatsu group. Diagnosis and treatment guidelines for ulcerative colitis and Crohn\u2019s disease 2026. http:\/\/www.ibdjapan.org\/pdf\/doc15.pdf. Accessed 9 Apr 2026."},{"issue":"10","key":"3757_CR5","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1007\/s12325-023-02605-y","volume":"40","author":"A Afzali","year":"2023","unstructured":"Afzali A, Lukanova R, Hennessy F, et al. Unmet needs in real-world advanced therapy-na\u00efve and -experienced patients with moderately to severely active ulcerative colitis in the United States. Adv Ther. 2023;40(10):4321\u201338. https:\/\/doi.org\/10.1007\/s12325-023-02605-y.","journal-title":"Adv Ther"},{"key":"3757_CR6","doi-asserted-by":"publisher","first-page":"e20260006","DOI":"10.62958\/j.cjap.2026.006","volume":"42","author":"MR Kumbhare","year":"2026","unstructured":"Kumbhare MR, Shaikh AS, Ide BR, Gode HS, Pagere ND, Porje RK. Etrasimod: a next-generation S1P receptor modulator for ulcerative colitis\u2014mechanistic insights and clinical progress. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2026;42:e20260006.\u00a0https:\/\/doi.org\/10.62958\/j.cjap.2026.006.","journal-title":"Zhongguo Ying Yong Sheng Li Xue Za Zhi"},{"key":"3757_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nri2974","volume":"11","author":"S Spiegel","year":"2011","unstructured":"Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11:403\u201315. https:\/\/doi.org\/10.1038\/nri2974.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3757_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1242\/dev.094805","volume":"141","author":"K Mendelson","year":"2014","unstructured":"Mendelson K, Evans T, Hla T. Sphingosine 1-phosphate signalling. Development. 2014;141(1):5\u20139. https:\/\/doi.org\/10.1242\/dev.094805.","journal-title":"Development"},{"key":"3757_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency. List of approved products. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html. Accessed 9 Apr 2026."},{"issue":"2","key":"3757_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf014","volume":"7","author":"F Hirai","year":"2025","unstructured":"Hirai F, Matsumoto T, Imai K, et al. Questionnaire survey of Japanese patients with inflammatory bowel disease and physicians on shared decision-making in advanced therapy: a web-based PAIR survey. Crohns Colitis 360. 2025;7(2):otaf014. https:\/\/doi.org\/10.1093\/crocol\/otaf014.","journal-title":"Crohns Colitis 360"},{"key":"3757_CR11","unstructured":"National Institute for Health and Care Excellence. Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over\u2014TA956. https:\/\/www.nice.org.uk\/guidance\/ta956. Accessed 9 Apr 2026."},{"issue":"1","key":"3757_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s41669-025-00619-6","volume":"10","author":"I Rodr\u00edguez-Lago","year":"2026","unstructured":"Rodr\u00edguez-Lago I, Mu\u00f1oz N\u00fa\u00f1ez F, Lucendo AJ, et al. Cost-effectiveness analysis of etrasimod compared with biologic therapies for the treatment of patients with moderately-to-severely active ulcerative colitis in Spain. PharmacoEconomics Open. 2026;10(1):121\u201342. https:\/\/doi.org\/10.1007\/s41669-025-00619-6.","journal-title":"PharmacoEconomics Open"},{"issue":"5","key":"3757_CR13","doi-asserted-by":"publisher","first-page":"e240225","DOI":"10.57264\/cer-2024-0225","volume":"14","author":"V Jairath","year":"2025","unstructured":"Jairath V, Raine T, Leahy TP, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis. J Comp Eff Res. 2025;14(5):e240225. https:\/\/doi.org\/10.57264\/cer-2024-0225.","journal-title":"J Comp Eff Res"},{"key":"3757_CR14","unstructured":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health. Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en_2024.pdf. Accessed 25 Mar 2026."},{"issue":"1","key":"3757_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43\u201351. https:\/\/doi.org\/10.1016\/j.jval.2019.10.005.","journal-title":"Value Health"},{"issue":"2 Suppl","key":"3757_CR16","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S68-80. https:\/\/doi.org\/10.1177\/0272989X98018002S09.","journal-title":"Med Decis Making"},{"issue":"18","key":"3757_CR17","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med"},{"issue":"2","key":"3757_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/jgh.16387","volume":"39","author":"S Yoshida","year":"2024","unstructured":"Yoshida S, Imai S, Fushimi K. Changes in surgery rates among hospitalized patients with inflammatory bowel disease in Japan from 2015 to 2019: a nationwide administrative database analysis. J Gastroenterol Hepatol. 2024;39(2):272\u20139. https:\/\/doi.org\/10.1111\/jgh.16387.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3757_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25218-x","volume":"12","author":"Y Yokoyama","year":"2022","unstructured":"Yokoyama Y, Ohta Y, Ogasawara S, et al. The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort. Sci Rep. 2022;12(1):21060. https:\/\/doi.org\/10.1038\/s41598-022-25218-x.","journal-title":"Sci Rep"},{"key":"3757_CR20","unstructured":"National Institute for Health and Care Excellence. Ustekinumab for moderately to severely active ulcerative colitis\u2014TA633. https:\/\/www.nice.org.uk\/guidance\/ta633. Accessed 9 Apr 2026."},{"key":"3757_CR21","unstructured":"National Institute for Health and Care Excellence. Upadacitinib for moderately to severely active ulcerative colitis\u2014TA856. https:\/\/www.nice.org.uk\/guidance\/ta856. Accessed 9 Apr 2026."},{"issue":"7","key":"3757_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/03007995.2022.2071041","volume":"38","author":"J Sah","year":"2022","unstructured":"Sah J, Teeple A, Muser E, Gutierrez C, Dassopoulos T. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases. Curr Med Res Opin. 2022;38(7):1093\u2013101. https:\/\/doi.org\/10.1080\/03007995.2022.2071041.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"3757_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/apt.13291","volume":"42","author":"P Rutgeerts","year":"2015","unstructured":"Rutgeerts P, Feagan BG, Marano CW, et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42(5):504\u201314. https:\/\/doi.org\/10.1111\/apt.13291.","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"3757_CR24","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376. https:\/\/doi.org\/10.1056\/NEJMoa050516.","journal-title":"N Engl J Med"},{"issue":"1","key":"3757_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000536146","volume":"9","author":"R Moroi","year":"2024","unstructured":"Moroi R, Kakuta Y, Nagai H, et al. Clinical utilization of generic drugs and biosimilars for ulcerative colitis treatment: insights from a nationwide database study in Japan. Inflamm Intest Dis. 2024;9(1):29\u201339. https:\/\/doi.org\/10.1159\/000536146.","journal-title":"Inflamm Intest Dis"},{"issue":"5","key":"3757_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40273-023-01254-x","volume":"41","author":"T Kobayashi","year":"2023","unstructured":"Kobayashi T, Hoshi M, Yuasa A, et al. Cost-effectiveness analysis of tofacitinib compared with biologics in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2023;41(5):589\u2013604. https:\/\/doi.org\/10.1007\/s40273-023-01254-x.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"3757_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40273-019-00841-1","volume":"38","author":"L Hernandez","year":"2020","unstructured":"Hernandez L, Kuwabara H, Shah A, et al. Cost-effectiveness analysis of vedolizumab compared with other biologics in anti-TNF-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2020;38(1):69\u201384. https:\/\/doi.org\/10.1007\/s40273-019-00841-1.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"3757_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287618","volume":"18","author":"M Nagahori","year":"2023","unstructured":"Nagahori M, Imai T, Nakashoji M, Tairaka A, Fernandez JL. A web-based survey on self-management for patients with inflammatory bowel disease in Japan. PLoS ONE. 2023;18(7):e0287618. https:\/\/doi.org\/10.1371\/journal.pone.0287618.","journal-title":"PLoS ONE"},{"issue":"7","key":"3757_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00595-007-3685-3","volume":"38","author":"M Itabashi","year":"2008","unstructured":"Itabashi M, Ikeuchi H, Araki T, et al. Effectiveness of leukocytapheresis in suppressing the occurrence of surgical site infections following surgery for ulcerative colitis. Surg Today. 2008;38(7):609\u201317. https:\/\/doi.org\/10.1007\/s00595-007-3685-3.","journal-title":"Surg Today"},{"issue":"1","key":"3757_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.amjsurg.2005.05.001","volume":"190","author":"K Arai","year":"2005","unstructured":"Arai K, Koganei K, Kimura H, et al. Incidence and outcome of complications following restorative proctocolectomy. Am J Surg. 2005;190(1):39\u201342. https:\/\/doi.org\/10.1016\/j.amjsurg.2005.05.001.","journal-title":"Am J Surg"},{"key":"3757_CR31","unstructured":"Ministry of Health, Labour and Welfare. Various Information of Medical Fee. https:\/\/shinryohoshu.mhlw.go.jp\/shinryohoshu\/. Accessed 9 Apr 2026."},{"key":"3757_CR32","unstructured":"Ministry of Health, Labour and Welfare. Medical Fee Information. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iryouhoken\/newpage_21053.html. Accessed 9 Apr 2026."},{"key":"3757_CR33","unstructured":"The Organization for Economic Co-operation and Development. Exchange rates. https:\/\/data.oecd.org\/conversion\/exchange-rates.html. Accessed 4 Jan 2026."},{"issue":"8","key":"3757_CR34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and Health Utilities Index Mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193\u2013202. https:\/\/doi.org\/10.1016\/j.jval.2021.03.010.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"3757_CR35","first-page":"A153","volume":"57","author":"A Woehl","year":"2008","unstructured":"Woehl A, Hawthorne A, McEwan P. The relation between disease activity, quality of life and health utility in patients with ulcerative colitis. Gut. 2008;57(Suppl 1):A153.","journal-title":"Gut"},{"issue":"9","key":"3757_CR36","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.cgh.2006.05.003","volume":"4","author":"KO Arseneau","year":"2006","unstructured":"Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4(9):1135\u201342. https:\/\/doi.org\/10.1016\/j.cgh.2006.05.003.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"35","key":"3757_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"M Stevenson","year":"2016","unstructured":"Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20(35):1\u2013610. https:\/\/doi.org\/10.3310\/hta20350.","journal-title":"Health Technol Assess"},{"key":"3757_CR38","unstructured":"Ministry of Health, Labour and Welfare. Abridged Life Tables\u00a0for Japan 2024. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/life\/life24\/index.html. Accessed 25 Mar 2026."},{"issue":"10","key":"3757_CR39","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/hec.1629","volume":"19","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ. 2010;19(10):1117\u201327. https:\/\/doi.org\/10.1002\/hec.1629.","journal-title":"Health Econ"},{"key":"3757_CR40","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Ozanimod. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/670605_2399019M1028_1_17. Accessed 9 Apr 2026."},{"key":"3757_CR41","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Etrasimod. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/672212_2399020F1021_1_01. Accessed 9 Apr 2026."},{"key":"3757_CR42","unstructured":"Ministry of Health, Labour and Welfare. National Health Insurance Drug Price List and Information on Generic Drugs (as of April 1, 2026). https:\/\/www.mhlw.go.jp\/topics\/2026\/04\/tp20260401-01.html. Accessed 9 Apr 2026."},{"issue":"4","key":"3757_CR43","doi-asserted-by":"publisher","first-page":"e240193","DOI":"10.57264\/cer-2024-0193","volume":"14","author":"V Jairath","year":"2025","unstructured":"Jairath V, Raine T, Leahy TP, et al. Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis. J Comp Eff Res. 2025;14(4):e240193. https:\/\/doi.org\/10.57264\/cer-2024-0193.","journal-title":"J Comp Eff Res"},{"issue":"11","key":"3757_CR44","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/ibd\/izy114","volume":"24","author":"B Wu","year":"2018","unstructured":"Wu B, Wang Z, Zhang Q. Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2018;24(11):2291\u2013302. https:\/\/doi.org\/10.1093\/ibd\/izy114.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"3757_CR45","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5217\/ir.2025.00118","volume":"24","author":"R Nomaru","year":"2026","unstructured":"Nomaru R, Takeda T, Takahashi A, et al. Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease. Intest Res.\u00a02026;24(3):552\u2013562.\u00a0https:\/\/doi.org\/10.5217\/ir.2025.00118.","journal-title":"Intest Res"},{"key":"3757_CR46","unstructured":"Ministry of Health, Labour and Welfare. High-cost medical expense benefit Program. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/iryouhoken\/juuyou\/kougakuiryou\/index.html. Accessed 9 Apr 2026."},{"issue":"13","key":"3757_CR47","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3748\/wjg.v30.i13.1871","volume":"30","author":"K Kojima","year":"2024","unstructured":"Kojima K, Watanabe K, Kawai M, et al. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. World J Gastroenterol. 2024;30(13):1871\u201386. https:\/\/doi.org\/10.3748\/wjg.v30.i13.1871.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"3757_CR48","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s00535-023-02048-w","volume":"58","author":"M Naganuma","year":"2023","unstructured":"Naganuma M, Kobayashi T, Kunisaki R, et al. Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis. J Gastroenterol. 2023;58(12):1198\u2013210. https:\/\/doi.org\/10.1007\/s00535-023-02048-w.","journal-title":"J Gastroenterol"},{"issue":"9","key":"3757_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12091991","volume":"12","author":"K Nomura","year":"2024","unstructured":"Nomura K, Shibuya T, Odakura R, et al. Comparison of the effectiveness of vedolizumab and ustekinumab in patients with ulcerative colitis: a real-world retrospective study. Biomedicines. 2024;12(9):1991. https:\/\/doi.org\/10.3390\/biomedicines12091991.","journal-title":"Biomedicines"},{"issue":"11","key":"3757_CR50","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/apt.17961","volume":"59","author":"S Akiyama","year":"2024","unstructured":"Akiyama S, Yokoyama K, Yagi S, et al. Efficacy and safety of filgotinib for ulcerative colitis: a real-world multicenter retrospective study in Japan. Aliment Pharmacol Ther. 2024;59(11):1413\u201324. https:\/\/doi.org\/10.1111\/apt.17961.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3757_CR51","doi-asserted-by":"publisher","first-page":"524","DOI":"10.5217\/ir.2024.00104","volume":"23","author":"S Hiraoka","year":"2025","unstructured":"Hiraoka S, Huang Z, Qin F, et al. Health-related quality of life, work productivity, and persisting challenges in treated ulcerative colitis patients: a Japanese National Health and Wellness Survey. Intest Res. 2025;23(4):524\u201340. https:\/\/doi.org\/10.5217\/ir.2024.00104.","journal-title":"Intest Res"},{"key":"3757_CR52","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Adalimumab. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112130_3999426G3027_1_12. Accessed 9 Apr 2026."},{"key":"3757_CR53","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Adalimumab biosimilar. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/430574_3999459G1029_1_08. Accessed 9 Apr 2026."},{"key":"3757_CR54","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Filgotinib. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/230867_3999053F1023_1_05. Accessed 9 Apr 2026."},{"key":"3757_CR55","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Golimumab. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/800155_3999433G1024_1_25. Accessed 9 Apr 2026."},{"key":"3757_CR56","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Infliximab. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400315_2399402F1026_1_48. Accessed 9 Apr 2026."},{"key":"3757_CR57","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Infliximab biosimilar. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/672212_2399406F1024_2_07. Accessed 9 Apr 2026."},{"key":"3757_CR58","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Tofacitinib. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/672212_3999034F1020_2_07. Accessed 9 Apr 2026."},{"key":"3757_CR59","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Upadacitinib. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112130_3999048G2024_1_17. Accessed 9 Apr 2026."},{"key":"3757_CR60","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Ustekinumab vial. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/800155_3999431A1022_1_13. Accessed 9 Apr 2026."},{"key":"3757_CR61","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Ustekinumab pen. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/800155_3999431G1025_1_21. Accessed 9 Apr 2026."},{"key":"3757_CR62","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Vedolizumab IV. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_2399405F1020_1_05. Accessed 9 Apr 2026."},{"key":"3757_CR63","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Vedolizumab SC. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_2399405G1025_1_05. Accessed 9 Apr 2026."},{"key":"3757_CR64","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Azathioprine. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112268_3999005F1059_X_09. Accessed 9 Apr 2026."},{"key":"3757_CR65","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u20145-ASA. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/670666_2399009F1149_3_02. Accessed 9 Apr 2026."},{"key":"3757_CR66","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Prednisolone. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/343018_2456001F1310_4_07. Accessed 9 Apr 2026."},{"key":"3757_CR67","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert\u2014Budesonide. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/111890_2399716K1020_1_08. Accessed 9 Apr 2026."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03757-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:45:09Z","timestamp":1788849909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03757-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":67,"alternative-id":["3757"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03757-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kazumasa Kamei, Miwa Enami, Masato Hoshi, and Akira Yuasa are full-time employees of Pfizer Japan Inc. Hiroyuki Matsuda, Katsuya Yamagami, and Yawen Dai are full-time employees of IQVIA Solutions Japan G.K., which received funding from Pfizer Japan Inc. to conduct this study. Ernest H Law is a full-time employee of Pfizer Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is entirely based on analyses of existing literature, and no new investigations involving human participants or animals were performed by the authors. Therefore, ethical approval and informed consent were not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}